• The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

  • Jan 30 2025
  • Length: 27 mins
  • Podcast

The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

Listen for free

View show details

  • Summary

  • We love to hear from our listeners. Send us a message.

    Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors. These vectors offer significant advantages in delivering large genetic payloads, a crucial factor in developing effective gene therapies. Sabzevari also discusses Precigen's recent BLA submission for PRGN-2012, which includes Phase 1/2 pivotal study results where over 50% of patients achieved Complete Response and more than 85% experienced decreased surgical interventions.

    Subscribe to the podcast!
    Apple | Spotify | YouTube
    Show more Show less
Show more Show less

What listeners say about The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available